Last Updated: November 16, 2026

ENJAYMO Drug Profile

« Back to Dashboard


Summary for Tradename: ENJAYMO
High Confidence Patents:0
Applicants:2
BLAs:1
Pharmacology for ENJAYMO
Mechanism of ActionClassical Complement Pathway Inhibitors
Established Pharmacologic ClassClassical Complement Pathway Inhibitor
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ENJAYMO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ENJAYMO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ENJAYMO Derived from Patent Text Search

No patents found based on company disclosures

ENJAYMO (Sutimlimab) Market Dynamics, Patent Protection, and Financial Trajectory

Last updated: September 15, 2026

ENJAYMO, Sanofi’s sutimlimab-jome, is the first FDA-approved treatment for hemolysis in adults with cold agglutinin disease, a rare autoimmune hemolytic anemia. Its commercial profile is driven by high unmet need, orphan-drug exclusivity, chronic intravenous treatment, and a limited competitive field. Sanofi’s reported sales increased from an initial launch base in 2022 to approximately €190 million in 2024, but the product remains a specialty asset rather than a mass-market franchise.

The principal commercial risks are restricted diagnosis of cold agglutinin disease, infusion-based administration, payer controls, off-label use of rituximab-based regimens, and potential competition from complement-pathway therapies. U.S. orphan-drug exclusivity runs to February 2029, while key biologic patent protection is expected to extend into the mid-2030s, subject to patent-term adjustment, patent-term extension, and claim scope.

What is ENJAMO and what disease does it treat?

ENJAYMO is sutimlimab-jome, a humanized monoclonal antibody that selectively inhibits complement component C1s. It blocks the classical complement pathway and reduces complement-mediated hemolysis in cold agglutinin disease.

The FDA approved ENJAYMO on February 4, 2022, for the treatment of hemolysis in adults with cold agglutinin disease. The approval was based principally on the CARDINAL and CADENZA clinical programs, which showed reductions in hemolysis and improvements in transfusion-related outcomes in selected patient populations (U.S. Food and Drug Administration, 2022a, 2022b).

How is ENJAYMO administered?

ENJAYMO is administered by intravenous infusion. The recommended regimen is weight-based:

Patient weight Dose
39 kg to less than 75 kg 6,500 mg
75 kg or more 7,500 mg

Treatment is given on day 0 and day 7, followed by dosing every two weeks. The need for repeated infusion-center visits affects both product economics and patient access.

How large is the ENJAYMO market?

The addressable population is limited by the rarity of cold agglutinin disease and by underdiagnosis. Published estimates commonly place disease prevalence at roughly 12,000 patients in the United States and Europe combined, although the number of diagnosed and treatment-eligible patients is lower and varies by epidemiologic methodology.

A commercial model for ENJAYMO depends on four factors:

  1. The number of patients diagnosed with primary cold agglutinin disease.
  2. The proportion with clinically meaningful hemolysis.
  3. The proportion able to receive chronic intravenous therapy.
  4. Net annual pricing after discounts and payer concessions.

ENJAYMO is positioned for patients with active hemolysis rather than every patient with a positive cold agglutinin test. Treatment demand is also influenced by disease severity, transfusion dependence, fatigue, infection risk, and the ability of hematologists to identify complement-mediated disease.

What is the competitive landscape for ENJAYMO?

ENJAYMO has no direct FDA-approved competitor specifically labeled for cold agglutinin disease as of the latest publicly available regulatory information. Its practical competition includes:

Competitive option Status in cold agglutinin disease Commercial impact
Rituximab Frequently used off label, alone or with chemotherapy Main established treatment alternative
Bendamustine plus rituximab Used off label in selected patients More intensive, generally not a direct substitute for all patients
Supportive transfusion and warming measures Standard supportive care Used alongside disease-directed therapy
Other complement inhibitors Development or approved for other diseases Potential future competition
Splenic or immunomodulatory approaches Limited use Relevant mainly in selected refractory disease

ENJAYMO’s strongest differentiator is rapid control of complement-mediated hemolysis without relying on B-cell depletion. Its commercial limitation is that it controls hemolysis but does not eliminate the underlying cold autoantibody clone.

What has been ENJAYMO’s financial trajectory?

Sanofi does not report ENJAYMO as a separate segment with a fully detailed operating-profit statement. Public disclosures report product sales within Sanofi’s Specialty Care portfolio. Based on Sanofi annual and quarterly reporting, ENJAYMO sales followed a rapid early-launch trajectory.

Fiscal year Approximate reported sales Commercial interpretation
2022 Approximately €25 million to €30 million Partial launch year after February approval
2023 Approximately €125 million to €130 million Broader diagnosis and treatment-center adoption
2024 Approximately €190 million to €200 million Continued penetration of diagnosed patients and recurring treatment

The figures above are rounded from Sanofi’s reported product disclosures and are presented as directional values rather than a separately audited ENJAYMO income statement (Sanofi, 2023, 2024, 2025).

What is driving ENJAYMO revenue growth?

Revenue growth has been supported by:

  • Expansion of the hematology treatment-center network.
  • Increased awareness of cold agglutinin disease.
  • Repeat dosing from chronic patients.
  • Use in patients with clinically significant hemolysis.
  • A lack of an equally targeted approved therapy.
  • Sanofi’s existing specialty-care infrastructure.

The product’s revenue curve is likely to flatten as the diagnosed patient pool matures. Future growth depends more on diagnosis, treatment duration, geographic expansion, and label expansion than on broad primary-care prescribing.

How much revenue exposure does Sanofi have?

ENJAYMO is financially immaterial to Sanofi’s consolidated revenue compared with Dupixent, vaccines, and other large franchises. Its strategic value is higher than its current revenue contribution because the product occupies an orphan hematology niche with premium pricing and long-duration treatment.

A €200 million annual product is meaningful within a rare-disease portfolio but does not materially alter Sanofi’s group earnings profile. The commercial downside from a competing therapy would therefore be concentrated in the Specialty Care portfolio rather than create a major company-wide revenue shock.

What patents protect ENJAYMO?

ENJAYMO is protected by a combination of biologic composition claims, antibody sequence claims, manufacturing claims, and potentially formulation or therapeutic-use claims. The relevant patent estate originated in the development programs of True North Therapeutics and Bioverativ and is now controlled commercially by Sanofi.

What was the acquisition and licensing history?

Bioverativ acquired True North Therapeutics in 2017 for approximately $825 million upfront, with additional contingent consideration. True North had developed sutimlimab, then known as TNT009 or BIVV009, for complement-mediated diseases.

Sanofi acquired Bioverativ in 2018 for approximately $11.6 billion. That transaction transferred Bioverativ’s hematology portfolio, including sutimlimab, to Sanofi (Sanofi, 2018).

The transaction was an acquisition rather than a conventional out-licensing deal. Sanofi therefore controls the principal commercial rights and the development strategy for ENJAYMO.

What is the expected patent term?

The principal U.S. composition-of-matter and antibody patents are expected to provide protection into the mid-2030s, subject to the specific patent family, patent-term adjustment, patent-term extension, terminal disclaimers, and enforceable claim scope.

A precise generic-entry date cannot be determined from the FDA approval date alone. Biologic exclusivity and patent expiry are separate concepts:

Protection type Expected position
FDA orphan-drug exclusivity Seven years from February 4, 2022, generally reaching February 2029
Biologic reference-product exclusivity Twelve years from approval, subject to statutory calculation and regulatory interpretation
Core composition patent protection Expected to extend into the 2030s
Formulation and manufacturing patents May expire on different dates and can create additional litigation issues
Method-of-use patents Scope depends on the claimed patient population and treatment method

The Orange Book does not function as the principal patent register for therapeutic biologics in the same manner as it does for small-molecule drugs. ENJAYMO’s patent and exclusivity analysis therefore requires review of FDA biologic records, USPTO patent records, patent-family data, and any future biosimilar litigation.

What is the FDA regulatory and exclusivity status of ENJAYMO?

ENJAYMO was approved under the biologics framework and received orphan-drug designation for cold agglutinin disease. Its initial approval was based on a clinical benefit package addressing hemolysis and transfusion-related outcomes.

When does ENJAYMO lose exclusivity?

The principal FDA orphan-drug exclusivity period is expected to run through February 2029. That period prevents FDA approval of the same drug for the same indication, subject to statutory exceptions.

Orphan exclusivity does not prevent all forms of competition. A competing biologic with a different molecular structure could potentially obtain approval if it independently demonstrates safety and effectiveness. Orphan exclusivity also does not block off-label use of existing drugs.

The practical loss-of-exclusivity date is more likely to be determined by biologic patent litigation and biosimilar development than by orphan exclusivity alone.

Is ENJAYMO listed in the Orange Book?

ENJAYMO is a biologic, so the Orange Book is not the primary source for its exclusivity and patent status. The relevant regulatory framework is the Public Health Service Act, including the biosimilar pathway created by the Biologics Price Competition and Innovation Act.

Are biosimilars or Paragraph IV challengers affecting ENJAYMO?

No publicly established Paragraph IV challenge is expected to apply to ENJAYMO in the conventional small-molecule sense. Paragraph IV certifications are associated with abbreviated new drug applications and Orange Book-listed patents. ENJAYMO is subject instead to the biologic patent-dispute procedures commonly known as the patent dance under the Public Health Service Act.

No publicly identified biosimilar launch or major biosimilar litigation had materially altered ENJAYMO’s U.S. commercial position through the latest broadly available company and FDA disclosures.

What biosimilar risks exist?

A biosimilar developer would face several barriers:

  • A relatively small commercial market.
  • Costly monoclonal-antibody clinical and analytical development.
  • Limited manufacturing capacity for complex biologics.
  • Potentially long-lived composition and process patents.
  • A narrow disease population.
  • The need to establish interchangeability or secure pharmacy and payer uptake.
  • The possibility that Sanofi uses additional formulation, manufacturing, or dosing patents.

The principal long-term risk is not a near-term generic-style erosion event. It is a gradual shift in treatment standards if another complement inhibitor, B-cell therapy, or oral therapy proves easier to administer or clinically broader.

What formulations and manufacturing rights protect ENJAYMO?

ENJAYMO’s commercial product is an intravenous monoclonal-antibody formulation supplied for dilution and infusion. Formulation claims may cover concentration, stabilizers, buffer systems, aggregation control, or storage conditions. Manufacturing claims may cover cell-line production, purification, viral clearance, and process controls.

These rights can raise the cost of biosimilar development, but they are usually less durable than core antibody or composition claims. A biosimilar developer may design around a formulation or process patent while still pursuing the same therapeutic target.

Manufacturing scale is a practical barrier because sutimlimab must meet biologic quality specifications, including potency, purity, aggregation, and consistency requirements. Sanofi’s manufacturing network and quality systems support supply reliability but do not alone prevent biosimilar entry.

What litigation and settlement risks affect ENJAYMO?

No major publicly reported U.S. patent settlement or commercial launch agreement involving an ENJAYMO biosimilar had materially changed the market position through the latest available disclosures.

Future litigation would likely involve:

  • Patent-listing and patent-dispute strategy.
  • Validity and enforceability of antibody and sequence claims.
  • Patent-term adjustment and terminal-disclaimer issues.
  • Biosimilar manufacturing and process patents.
  • The scope of interchangeability and substitution.
  • Confidential settlement dates for biosimilar entry.

An early biosimilar settlement could establish an entry date before the latest patent expiry. Conversely, a strong composition patent could delay entry even after FDA regulatory exclusivity ends.

How strong is the ENJAYMO patent estate?

ENJAYMO has a relatively strong commercial protection profile because it combines orphan exclusivity with biologic manufacturing complexity and expected mid-2030s patent protection. The estate is stronger than a product protected only by method-of-use patents.

Its principal vulnerabilities are:

  • Limited disease prevalence, which may reduce the expected value of litigation.
  • Potential design-around strategies for antibody claims.
  • The distinction between treating hemolysis and treating the underlying disease.
  • Possible competition from different complement-pathway mechanisms.
  • The limited ability of patents to stop off-label use of older therapies.

The strongest patent position would be based on valid composition, sequence, and target-specific claims. Formulation and process patents are useful supplementary barriers but generally have narrower enforcement value.

How does ENJAYMO compare with other complement inhibitors?

Product Target Main approved use Administration Relevance to ENJAYMO
ENJAYMO C1s Hemolysis in cold agglutinin disease IV every two weeks after loading Directly targeted approved therapy
SOLIRIS C5 PNH, aHUS and other indications IV Different disease and mechanism
ULTOMIRIS C5 PNH, aHUS and other indications IV at longer intervals May compete for complement-treatment expertise
FABHALTA Factor B PNH and other complement-mediated indications Oral Potential future competitive benchmark
Empaveli C3 PNH Subcutaneous Different disease and delivery profile

These products are not interchangeable with ENJAYMO based solely on mechanism. Their commercial relevance lies in demonstrating payer acceptance and clinical demand for complement inhibition.

What generic launch scenarios exist for ENJAYMO?

Three launch scenarios are commercially relevant:

Scenario 1: No biosimilar before the mid-2030s

Sanofi retains premium pricing and recurring revenue growth through continued diagnosis and treatment expansion. This is the most favorable scenario for the current patent estate.

Scenario 2: Early biosimilar settlement

A biosimilar enters after orphan exclusivity but before expiration of all relevant patents. Revenue erosion is delayed but may begin before the mid-2030s. Sanofi could retain share through contracting, infusion-center relationships, and patient-support programs.

Scenario 3: Therapeutic displacement

A competing oral or less frequently administered complement inhibitor gains approval for cold agglutinin disease. This could reduce ENJAYMO use without requiring biosimilar entry. The impact would be greatest in patients who dislike recurring infusions or whose payers favor oral treatment.

Geographic erosion would likely occur first in markets with aggressive biosimilar substitution and centralized reimbursement. The United States may preserve higher net pricing longer, but payer restrictions could increase as the product matures.

Key Takeaways

  • ENJAYMO is the first FDA-approved therapy specifically indicated for hemolysis in adults with cold agglutinin disease.
  • Sanofi’s sales trajectory rose from roughly €25 million to €30 million in 2022 to approximately €190 million to €200 million in 2024.
  • The product benefits from seven years of orphan-drug exclusivity, expected to run to February 2029.
  • Core patent protection is expected to extend into the mid-2030s, although exact entry timing depends on individual patent families and litigation.
  • Conventional Paragraph IV risk is limited because ENJAYMO is a biologic; future competition is more likely to arise through biosimilar litigation or a different complement inhibitor.
  • The key commercial constraint is the small, underdiagnosed patient population.
  • The largest strategic risks are competing oral therapies, alternative complement mechanisms, and payer resistance to chronic infusion treatment.
  • Sanofi’s acquisition of Bioverativ gave it control of sutimlimab and the associated development and commercial rights.

Frequently Asked Questions

Is ENJAYMO a biologic or a small-molecule drug?

ENJAYMO is a biologic monoclonal antibody. Its active ingredient is sutimlimab-jome.

Is ENJAYMO approved in Europe?

Sutimlimab has received regulatory authorization in major markets outside the United States, including Europe, for treatment of hemolytic anemia due to cold agglutinin disease. Market access and reimbursement terms differ by country.

Can rituximab replace ENJAYMO?

Rituximab is used off label in cold agglutinin disease, but it has a different mechanism and slower disease-control profile. It is not an FDA-approved substitute for ENJAYMO’s labeled indication.

Does ENJAYMO cure cold agglutinin disease?

ENJAYMO controls complement-mediated hemolysis but does not generally eliminate the underlying cold-reactive B-cell clone. Long-term treatment may therefore be required.

What is the biggest threat to ENJAYMO sales?

The greatest long-term threat is likely a competing therapy with oral administration, longer dosing intervals, or broader efficacy in cold agglutinin disease rather than a conventional generic launch.

References

  1. Sanofi. (2018). Sanofi to acquire Bioverativ for $105 per share in cash. Sanofi.

  2. Sanofi. (2023). 2022 annual report. Sanofi.

  3. Sanofi. (2024). 2023 annual report. Sanofi.

  4. Sanofi. (2025). 2024 annual report. Sanofi.

  5. U.S. Food and Drug Administration. (2022a). FDA approves treatment for adults with rare blood disorder. U.S. Department of Health and Human Services.

  6. U.S. Food and Drug Administration. (2022b). ENJAYMO prescribing information. U.S. Department of Health and Human Services.

  7. U.S. Food and Drug Administration. (2023). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.